Paolo De Coppi – VJRegenMed https://mirror.vjregenmed.com The Video Journal of Regenerative Medicine Fri, 28 Jan 2022 09:18:21 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.2 https://d2xz56kaqxj8if.cloudfront.net/wp-content/uploads/2023/09/12102509/VJR-Favicon.png Paolo De Coppi – VJRegenMed https://mirror.vjregenmed.com 32 32 Advances in organ bioengineering https://mirror.vjregenmed.com/video/6mjppf8c9qi-advances-in-organ-bioengineering/ Tue, 04 Jan 2022 17:52:19 +0000 http://13.40.107.223/video/6mjppf8c9qi-advances-in-organ-bioengineering/ Paolo De Coppi, MD, PhD, FMedSci, UCL Great Ormond Street Institute of Child Health & NIHR Biomedical Research Centre, London, UK, provides an overview of the current landscape of bioengineering for organ replacement and some of the key considerations during the development of tissue-engineered organs, including the types of cell and polymers used. He notes that for the regeneration of simple tissues, autologous somatic cells may be sufficient, however, for more complex organs, pluripotent stem cells would likely be required, which would require immunosuppression upon implantation in order to avoid tissue rejection. Dr De Coppi also describes ongoing research into the use of biliary organoids for the repair of the damaged liver. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

]]>
Driving the translation of intestinal tissue engineering https://mirror.vjregenmed.com/video/imwedre8ygw-driving-the-translation-of-intestinal-tissue-engineering/ Tue, 04 Jan 2022 17:52:17 +0000 http://13.40.107.223/video/imwedre8ygw-driving-the-translation-of-intestinal-tissue-engineering/ Paolo De Coppi, MD, PhD, FMedSci, UCL Great Ormond Street Institute of Child Health & NIHR Biomedical Research Centre, London, UK, describes ongoing research aiming to address challenges facing the development of tissue engineering strategies for the treatment of intestinal failure and their translation into patients. While it has been demonstrated that organoid technology can used to replace the intestinal mucosa, the development of Good Manufacturing Practice (GMP)-compliant methods for organoid expansion are required before human transplantation. Given the organ complexity of the intestine, instead of engineering the entire intestine, ongoing research is focused on engineering a functional small intestine mucosa which could be transplanted into the large intestine. This interview took place during the International Society for Cell & Gene Therapy (ISCT) Annual Meeting 2021.

]]>